Tadalafil Tablet
Product Images NDC 50090-5641

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-5641). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905641)

The label for Tadalafil 20 mg oral tablets by A-S Medication Solutions includes the NDC 50090-5641-0. It states the product contains 30 film-coated tablets, each with 20 mg of Tadalafil. Storage instructions specify keeping the product at 68 to 77 degrees Fahrenheit. The label also contains a QR code, a lot number field, and distribution details from Libertyville, IL.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks (0 to 12), and the y-axis shows score change from 0 to -6. The Tadalafil group shows a greater decrease in IPSS score over time compared to placebo, with a significant difference at 12 weeks (p<0.01).*

FDA Label Image

Figure1 (Tadalafil Figure1)

A set of four line graphs showing the difference in blood pressure measurements (systolic and diastolic) between tadalafil and placebo over time (up to 96 hours). The graphs illustrate standing systolic and diastolic blood pressure, and supine systolic and diastolic blood pressure, highlighting the changes at different time points after tadalafil administration.*

FDA Label Image

Figure2 (Tadalafil Figure2)

A figure showing two line graphs of blood pressure changes over 24 hours post-dose. The top graph depicts standing systolic blood pressure (mmHg) changes, and the bottom graph shows supine systolic blood pressure (mmHg) changes. Both graphs compare the effects of Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg over time.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph showing the effect on systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with doxazosin at two doses: 8 mg and 20 mg of tadalafil, all given at 08:00. The graph compares four groups: 20 mg tadalafil with doxazosin, placebo with doxazosin at 8 mg, 20 mg tadalafil with doxazosin at 8 mg, and placebo with doxazosin at 20 mg. The y-axis shows systolic blood pressure changes ranging from -20 to 20 mmHg, and the x-axis shows time in hours.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours). It compares three dosing regimens: single 20-mg tadalafil dose, single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration, illustrating their pharmacokinetic profiles.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment between Tadalafil 5 mg and placebo groups. The X-axis represents duration of treatment in weeks, and the Y-axis represents change from baseline in IPSS Total Score, showing greater improvement with Tadalafil 5 mg. Statistical significance is indicated (p<0.01).*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment period. It compares Tadalafil 5 mg with placebo, illustrating that Tadalafil results in a greater decrease in score. The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline. Significant difference indicated at p<0.01.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph showing the least-squares mean change from baseline over weeks of therapy (0, 12, and 26) comparing Tadalafil/Finasteride and Placebo/Finasteride groups. The graph includes treatment difference markers and significance levels (p<0.001 and p<0.05) at weeks 12 and 26.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure diagram of the active ingredient Tadalafil, showing its molecular framework with labeled atoms and bonds, as presented in the FDA Structured Product Labeling.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.